ArticleFrontiers in cell and developmental biology2026
Decoding NETosis-associated immune dysregulation in diffuse large B-cell lymphoma through integrative multi-omics and machine learning.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignancy driven by complex immune dysregulation, yet the role of NETosis, a distinct neutrophil immune effector program, in the tumor immune microenvironment and patient prognosis remains poorly defined. This study leveraged an integrative multi-omics and machine learning framework to elucidate the immunological implications of NETosis-related genes (NETosis-RGs) in DLBCL. Methods: NETosis-RGs were identified from transcriptomic profiles of DLBCL versus control tissues (GSE32018). Prognostic candidates were screened by univariate Cox regression and modeled using five machine learning algorithms, with the Random Survival Forest (RSF) model selected for risk stratification. Bulk and single-cell transcriptomic data were integrated to resolve the immune landscape, while ceRNA networks and m Results: The RSF-based model, incorporating five key NETosis-RGs (AKT1, SLC25A37, FPR2, TLR7, F3), robustly stratified patients into high- and low-risk groups exhibiting systematically distinct immune architectures-spanning differential immune cell infiltration, stromal/immune scores, and immune checkpoint expression. Single-cell transcriptomic analysis further revealed that these prognostic genes were predominantly expressed in monocytes and M1 macrophages and displayed dynamic regulation along myeloid/macrophage differentiation trajectories, suggesting their role as potential modulators of the immunosuppressive-to-inflammatory transition within the DLBCL microenvironment. Complementary analyses revealed multi-layered regulatory mechanisms, including m Conclusion: By integrating multi-omics data with machine learning, this study delineates a novel NETosis-centered immune signature that refines prognostic stratification and provides mechanistic insights into monocyte/macrophage-mediated immune dysregulation in DLBCL. The findings offer a framework for future immunomodulatory biomarker development and the development of precision therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.